The following was released this morning:
Wednesday May 27, 9:01 am Eastern Time
Company Press Release
Howard Jones, Ph.D., Appointed to Board of Synthetic Blood International
KETTERING, Ohio--(BUSINESS WIRE)--May 27, 1998--Howard Jones, Ph.D., president of the biopharmaceutical business unit of
Curative Health Services has been appointed to the board of directors of Synthetic Blood International Inc., (SYBD). He started his
career with Merck Research Laboratories where he discovered Clinoril, a rheumatoid arthritis drug with annual sales of $400 million.
At Curative, Dr. Jones is responsible for R&D plus licensing, selling and manufacturing their wound healing technology that
incorporates growth factors from the patients own blood. Dr. Jones has more than 84 U.S. patents issued for his biopharmaceutical
developments. He has more than 30 years experience in directing research and development of new drugs at Revlon, Bristol-Myers
Squibb, Amylin Pharmaceuticals and Cypros Pharmaceuticals, a San Diego-based company he co-founded in 1992.
''Dr. Jones brings the vast experience of directing and managing more than 40 regulatory submissions to the Food and Drug
Administration,'' said Robert Nicora, Synthetic Blood International president and chief executive officer. ''His experience in securing
financing from venture partners at Cypros, a development stage company similar to Synthetic Blood and at Curative is invaluable.''
Dr. Jones was a Fullbright Scholar. He served as research assistant in the chemistry department at UCLA after graduating with
honors from the University of Leeds in England. He is a member of the Royal Society of Medicine, the American Chemical Society,
the Chemical Society of England and the New York Academy of Sciences.
Nicora, who joined the company in March, was also appointed to serve as a director at the May meeting of the board of directors.
SYBD is developing Fluorovent, to assist breathing in patients with lung problems, Oxycyte, a substitute oxygen carrier in the
blood stream and an implantable biosensor for continuously noninvasive monitoring of blood glucose levels in diabetics.
SYBD is located in Kettering, Ohio. The Company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD.
Contact:
Synthetic Blood International Inc.
Joan Mahan, 800/809-6054 |
